Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for CX-2051 in Cancer, Metastatic colorectal cancer. The expected timing is based on the latest available company guidance and may change.
CTMX-2051-101 study. 1/24/24- IND cleared. 4/24- First patient dosed. 5/12/25- Interim data reported. 11/6/25- Data update by Q1 2026. Ph1b CRC combo study with bevacizumab to start Q1 2026. 11/06/25:- Reiterated Ph1 data update, 1b CRC in Q1 2026. 01/08/26:- Varseta-M Ph1 CRC expansion update Q1 2026. Bevacizumab combo starts Q1 2026; initial data by H1 2027.03/16/26:- Ph1 expansion data positive; FDA talks Mid-2026. More data at meetings 2026. Ph1b/2 chemo combo End-2026. Expansion cohorts in additional indications planned 2H 2026.05/07/26:- Dose optimization enrolled 40 CRC pts; extra Ph1 data H2 2026. Bev combo data 1H 2027; chemo/non-CRC 2H 2026. 08/06/26:- Ph1 data due year-end 2026. Combo study starts Q4 2026. Bev data H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.